Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Ablynx NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Ablynx NV, Medical Devices Deals, 2011 to YTD 2017 10
Ablynx NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Ablynx NV, Pharmaceuticals & Healthcare, Deal Details 13
Private Equity 13
BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 13
Partnerships 14
Ablynx Enters into Research Agreement with Genzyme 14
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 15
Taiwan Liposome and Ablynx Enter into Research Agreement 16
Merck Serono And Ablynx Extend Co-Discover And Development Agreement For Nanobodies 17
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 18
Ablynx Extends Co-development Agreement With Boehringer Ingelheim For Nanobody Therapeutics 19
Ablynx Enters Into Third Co-Discovery And Co-Development Agreement With Merck Serono 20
Licensing Agreements 21
Sanofi Enters into Licensing Agreement with Ablynx 21
Novo Nordisk Enters into Licensing Agreement with Ablynx 22
Taisho Pharma Enters into Licensing Agreement with Ablynx 23
Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 24
Merck Expands Licensing Agreement with Ablynx 25
Ablynx Enters Into Licensing Agreement With Eddingpharm 27
Equity Offering 29
Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 29
Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 31
Ablynx Amends Private Placement of Shares 32
Ablynx Raises USD1.05 Million Through Exercise of Warrants 34
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 35
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 36
Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 37
Ablynx Raises USD82.6 Million in Private Placement of Shares 38
Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 40
Ablynx Raises USD1.4 Million upon Exercise of Warrants 41
Ablynx Raises USD57 Million in Private Placement of Shares 42
Ablynx Completes Private Placement Of Shares For US$1.2 Million Upon Exercise Of Warrants 44
Ablynx Completes Private Placement Of Shares For US$41 Million 45
Debt Offering 46
Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 46
Acquisition 47
Sofinnova Divests Its Stake In Ablynx For US$29.4 Million 47
Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 48
Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 49
Ablynx NV – Key Competitors 50
Ablynx NV – Key Employees 51
Ablynx NV – Locations And Subsidiaries 52
Head Office 52
Recent Developments 53
Financial Announcements 53
Nov 16, 2017: Ablynx Announces Results For The First Nine Months Of 2017 And A Year-To-Date Business Update 53
Aug 24, 2017: Ablynx Announces 2017 Half Year Results and Year-to-date Business Update 55
May 11, 2017: Ablynx Reports Financial Results for the First Three Months Of 2017 and a Year-To-Date Business Update 58
Feb 23, 2017: Ablynx Announces 2016 Full Year Results 60
Nov 23, 2016: Ablynx Announces Results For The First Nine Months Of 2016 And A Year-To-Date Business Update 61
Aug 25, 2016: Ablynx Announces 2016 Half-year Results And Year-to-date Business Update 63
May 12, 2016: Ablynx Reports Financial Results For The First Three Months Of 2016 And Provides Business Update Year-To-Date 67
Feb 25, 2016: Ablynx Announces 2015 Full Year Results 69
Corporate Communications 71
Jul 17, 2017: Ablynx Proposes Appointment of Mrs Hilde Windels as a New Independent Director 71
Jun 13, 2017: Ablynx Appoints Markus Ewert As Chief Business Officer 72
Mar 07, 2017: Merck reports positive data from Phase Ib trial of M1095 in psoriasis patients 73
Clinical Trials 74
Jan 11, 2017: Ablynx Initiates Phase IIb “Respire” Study of its Inhaled Anti-RSV Nanobody, Alx-0171, For Treatment of RSV Infections In Hospitalised Infants 74
May 26, 2016: Ablynx To Present A Post-Hoc Analysis Of The Phase II Titan Study With Caplacizumab In Acquired Ttp Patients At The 21St Congress Of The European Hematology Association 76
Feb 11, 2016: New England Journal Of Medicine Publishes Ablynx Phase II Titan Study Of Caplacizumab in Patients With Acquired TTP 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78
Ablynx NV, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Ablynx NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Ablynx NV, Deals By Therapy Area, 2011 to YTD 2017 9
Ablynx NV, Medical Devices Deals, 2011 to YTD 2017 10
Ablynx NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 13
Ablynx Enters into Research Agreement with Genzyme 14
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 15
Taiwan Liposome and Ablynx Enter into Research Agreement 16
Merck Serono And Ablynx Extend Co-Discover And Development Agreement For Nanobodies 17
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 18
Ablynx Extends Co-development Agreement With Boehringer Ingelheim For Nanobody Therapeutics 19
Ablynx Enters Into Third Co-Discovery And Co-Development Agreement With Merck Serono 20
Sanofi Enters into Licensing Agreement with Ablynx 21
Novo Nordisk Enters into Licensing Agreement with Ablynx 22
Taisho Pharma Enters into Licensing Agreement with Ablynx 23
Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 24
Merck Expands Licensing Agreement with Ablynx 25
Ablynx Enters Into Licensing Agreement With Eddingpharm 27
Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 29
Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 31
Ablynx Amends Private Placement of Shares 32
Ablynx Raises USD1.05 Million Through Exercise of Warrants 34
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 35
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 36
Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 37
Ablynx Raises USD82.6 Million in Private Placement of Shares 38
Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 40
Ablynx Raises USD1.4 Million upon Exercise of Warrants 41
Ablynx Raises USD57 Million in Private Placement of Shares 42
Ablynx Completes Private Placement Of Shares For US$1.2 Million Upon Exercise Of Warrants 44
Ablynx Completes Private Placement Of Shares For US$41 Million 45
Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 46
Sofinnova Divests Its Stake In Ablynx For US$29.4 Million 47
Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 48
Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 49
Ablynx NV, Key Competitors 50
Ablynx NV, Key Employees 51
